Preparation of cationic proteoliposomes using cell-free membrane protein synthesis: the chaperoning effect of cationic liposomes

Ando, Mitsuru; Sasaki, Yoshihiro; Akiyoshi, Kazunari

doi:10.1039/d0ra05825d

Cited by 7 publications

(4 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Classically, LPs do not contain any proteins in the lipid bilayer or intraluminal space. However, different studies attempted to design proteoliposomes (proteo-LPs) that incorporate proteins [ 51 , 52 , 53 ]. Proteo-LPs have been employed as tools for studying lipid-protein and protein-protein interactions as well as topological features of different membrane-associated proteins [ 54 ].…”

Section: Structure and Composition Of Liposomes And Extracellular Ves...mentioning

confidence: 99%

Liposomes or Extracellular Vesicles: A Comprehensive Comparison of Both Lipid Bilayer Vesicles for Pulmonary Drug Delivery

et al. 2023

View full text Add to dashboard Cite

The rapid and non-invasive pulmonary drug delivery (PDD) has attracted great attention compared to the other routes. However, nanoparticle platforms, like liposomes (LPs) and extracellular vesicles (EVs), require extensive reformulation to suit the requirements of PDD. LPs are artificial vesicles composed of lipid bilayers capable of encapsulating hydrophilic and hydrophobic substances, whereas EVs are natural vesicles secreted by cells. Additionally, novel LPs-EVs hybrid vesicles may confer the best of both. The preparation methods of EVs are distinguished from LPs since they rely mainly on extraction and purification, whereas the LPs are synthesized from their basic ingredients. Similarly, drug loading methods into/onto EVs are distinguished whereby they are cell- or non-cell-based, whereas LPs are loaded via passive or active approaches. This review discusses the progress in LPs and EVs as well as hybrid vesicles with a special focus on PDD. It also provides a perspective comparison between LPs and EVs from various aspects (composition, preparation/extraction, drug loading, and large-scale manufacturing) as well as the future prospects for inhaled therapeutics. In addition, it discusses the challenges that may be encountered in scaling up the production and presents our view regarding the clinical translation of the laboratory findings into commercial products.

show abstract

Section: Structure and Composition Of Liposomes And Extracellular Ves...mentioning

confidence: 99%

Liposomes or Extracellular Vesicles: A Comprehensive Comparison of Both Lipid Bilayer Vesicles for Pulmonary Drug Delivery

et al. 2023

View full text Add to dashboard Cite

show abstract

“…[54] It has been reported that membrane proteins are incorporated into liposome membranes by PUREsystem expression in the presence of liposomes. [27,55] In this section, membrane protein expression was performed in the presence of lipid membrane-coated particles, and the function of the membrane proteins incorporated into the surface of the particles was investigated. The Spike protein (S protein) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was selected as the membrane protein in this study.…”

Section: Functionalization Of Lipid Membrane-coated Nanoparticles Wit...mentioning

confidence: 99%

“…[ 26 ] In addition, it has been shown that modification of proteins and other biomolecules on the membrane surface can lead to the development of smart drug delivery system (DDS) carriers with bioinspired functions. [ 27 ] However, owing to their low in vivo stability and low efficiency of drug incorporation into the inner water layer, there are still challenges in developing a highly efficient DDS using lipid bilayer membranes. [ 28,29 ] To overcome these problems, materials have been developed with the lipid membrane as a coating on the surface of core nanoparticles.…”

Section: Introductionmentioning

confidence: 99%

A Facile Method to Coat Nanoparticles with Lipid Bilayer Membrane: Hybrid Silica Nanoparticles Disguised as Biomembrane Vesicles by Particle Penetration of Concentrated Lipid Layers

Mizuta

Inoue

Sasaki

et al. 2023

Small

Self Cite

View full text Add to dashboard Cite

Natural membrane vesicles, including extracellular vesicles and enveloped viruses, participate in various events in vivo. To study and manipulate these events, biomembrane‐coated nanoparticles inspired by natural membrane vesicles are developed. Herein, an efficient method is presented to prepare organic–inorganic hybrid materials in high yields that can accommodate various lipid compositions and particle sizes. To demonstrate this method, silica nanoparticles are passed through concentrated lipid layers prepared using density gradient centrifugation, followed by purification, to obtain lipid membrane‐coated nanoparticles. Various lipids, including neutral, anionic, and cationic lipids, are used to prepare concentrated lipid layers. Single‐particle analysis by imaging flow cytometry determines that silica nanoparticles are uniformly coated with a single lipid bilayer. Moreover, cellular uptake of silica nanoparticles is enhanced when covered with a lipid membrane containing cationic lipids. Finally, cell‐free protein expression is applied to embed a membrane protein, namely the Spike protein of severe acute respiratory syndrome coronavirus 2, into the coating of the nanoparticles, with the correct orientation. Therefore, this method can be used to develop organic–inorganic hybrid nanomaterials with an inorganic core and a virus‐like coating, serving as carriers for targeted delivery of cargos such as proteins, DNA, and drugs.

show abstract

“…In particular, hybrid vesicles containing PEG modifications have an increased uptake efficiency compared to unmodified EVs. With regard to constructing hybrid EVs using liposomes to incorporate viral fusogenic proteins that induce fusion under acidic conditions, it is possible to reconstitute functional membrane proteins into liposomes in one step by cell-free protein synthesis [ 161 , 162 , 163 ].…”

Section: Drug Delivery System By Extracellular Vesiclementioning

confidence: 99%

Extracellular Vesicle-Based SARS-CoV-2 Vaccine

Matsuzaka

Yashiro

2023

Vaccines

View full text Add to dashboard Cite

Messenger ribonucleic acid (RNA) vaccines are mainly used as SARS-CoV-2 vaccines. Despite several issues concerning storage, stability, effective period, and side effects, viral vector vaccines are widely used for the prevention and treatment of various diseases. Recently, viral vector-encapsulated extracellular vesicles (EVs) have been suggested as useful tools, owing to their safety and ability to escape from neutral antibodies. Herein, we summarize the possible cellular mechanisms underlying EV-based SARS-CoV-2 vaccines.

show abstract

Preparation of cationic proteoliposomes using cell-free membrane protein synthesis: the chaperoning effect of cationic liposomes

Abstract: The preparation method of cationic proteoliposomes is established using a cell-free membrane protein synthesis in the presence of cationic liposomes.

Cited by 7 publications

References 38 publications

Liposomes or Extracellular Vesicles: A Comprehensive Comparison of Both Lipid Bilayer Vesicles for Pulmonary Drug Delivery

Liposomes or Extracellular Vesicles: A Comprehensive Comparison of Both Lipid Bilayer Vesicles for Pulmonary Drug Delivery

A Facile Method to Coat Nanoparticles with Lipid Bilayer Membrane: Hybrid Silica Nanoparticles Disguised as Biomembrane Vesicles by Particle Penetration of Concentrated Lipid Layers

Extracellular Vesicle-Based SARS-CoV-2 Vaccine

Contact Info

Product

Resources

About